Lunai Bioworks Inc.

Listed Company

LNAICIK 0001527728NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Jun 30

Period

FY 2025

Revenue

—

Net Income

$-178.01M

Total Assets

$8.23M

Equity

$-21.35M

Shares Out

24.19M

Op. Cash Flow

$-7.87M

Business

Lunai Bioworks Inc. operates through three subsidiaries—Renovaro Biosciences, Renovaro Cube and BioSymetrics—to advance biotechnology and AI-driven healthcare technologies. It develops allogeneic cell and gene therapy candidates for oncology and other serious diseases, an Explainable AI multi-omic diagnostic platform for early cancer detection, recurrence monitoring, and treatment response prediction, and AI-enabled biomarker discovery and experimental screening for drug discovery. The company’s key divisions include therapeutics (Renovaro Biosciences), AI diagnostics and liquid‑biopsy products (Renovaro Cube), and multimodal bioinformatics with in vivo validation (BioSymetrics). It targets hospitals, clinics, pharmaceutical and research partners and plans to commercialize via service laboratories, third‑party labs and strategic partnerships across EMEA and the United States.

Summary from filing dated 2025-09-29

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
General and administrative	18	25	15	14	8
Research and development	537,428	3	4	8	16
Intangible asset impairment	—	43	19	—	—
Goodwill impairment	170	12	0	—	—
Depreciation and amortization	129,095	121,859	113,496	123,590	123,535
Total Operating Expenses	189	82	39	116	23
LOSS FROM OPERATIONS	−189	−82	−39	−116	−23
Change in fair value of contingent consideration	12	−3	0	3	−3
Loss on extinguishment of debt	0	−1	0	—	—
Change in fair value of equity securities	−112,149	—	—	—	—
Interest expense	−725,684	−1	−580,344	—	—
Interest income and other income (expense)	116,346	−1	−126,620	—	—
Total Other Income (Expense)	11	−7	−1	3	−3
NET LOSS	−178	−88	−40	−113	−27
BASIC NET LOSS PER COMMON SHARE	−1.08	−0.91	−0.71	−2.16	—
DILUTED NET LOSS PER COMMON SHARE	−1.08	−0.91	−0.71	−2.16	—
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC	165	98	56	53	—
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED	165	98	56	53	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Cash	92,700	220,467	2	9	21
Insurance receivable	0	1	0	—	—
Investment in equity securities	387,851	—	—	—	—
Prepaids and other assets	566,081	668,929	690,925	392,996	234,583
Total Current Assets	1	2	3	10	21
Property and equipment, net	367,843	482,121	508,989	586,536	719,364
Definite life intangible assets, net	14,994	30,043	—	—	—
Software platform	143,000	—	—	—	—
Trademarks	8,000	—	—	—	—
Goodwill	6	159	12	12	12
Deposits and other assets	—	19,849	21,741	68,635	20,984
Operating lease right-of-use assets	687,371	1	913,985	1	1
Total Other Assets	7	161	55	74	168
TOTAL ASSETS	8	163	58	85	190
Accounts payable trade	13	9	5	1	320,559
Accrued expenses	6	5	723,173	1	1
Other current liabilities	378,282	295,361	184,733	220,685	90,602
Contingent consideration liability	630,000	12	0	—	—
Convertible notes payable	245,000	245,000	0	—	1
Current portion of operating lease liabilities	313,047	493,553	193,422	253,636	292,409
Notes payable	4	—	—	—	—
Notes payable related parties, net	6	2	5	—	—
Total Current Liabilities	29	30	11	6	2
Operating lease liabilities, net of current portion	424,547	842,389	775,587	985,699	1
Total Non-Current Liabilities	424,547	842,389	775,587	6	13
Total Liabilities	30	31	12	12	15
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding	0	0	0	—	—
Common stock, par value $0.0001, 350,000,000 shares authorized, 177,392,907 shares issued and outstanding at June 30, 2025; 158,452,644 shares issued and outstanding at June 30, 2024	17,741	15,847	6,371	5,302	5,222
Additional paid-in capital	478	465	291	277	266
Accumulated deficit	−510	−332	−244	−204	−91
Accumulated other comprehensive (loss)	11	−170,846	−29,882	−30,436	−10,834
Total Stockholders Equity (Deficit)	−21	132	47	73	175
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT)	8	163	58	85	190

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Depreciation and amortization	129,095	121,859	113,496	123,590	123,534
Loss on extinguishment of debt	—	1	—	—	—
Non-cash stock-based compensation expense	3	5	4	—	—
Non-cash restricted shares issued for services rendered	2	5	228,000	—	—
Amortization of discount on note payable	32,024	580,605	348,621	297,212	296,505
Other receivables	1	−1	46	1,594	342
Prepaid expenses/deposits	1	1	1	461,310	733,739
Accounts payable	3	4	4	1	−272,318
Other current liabilities	−26,477	0	−54,060	24,056	30,004
Operating leases, net	−16,086	11,284	−27,224	−13,516	—
Accrued expenses	499,330	5	−578,809	−139,641	—
NET CASH USED IN OPERATING ACTIVITIES	−8	−11	−12	−16	−21
Investment in equity securities	−500,000	0	—	—	—
Notes receivable prior to acquisition	0	−1	0	—	—
Cash received from acquisition, net	0	65,851	0	—	—
Purchase of property and equipment	—	−70,430	−29,774	−5,156	−48,892
NET CASH USED IN INVESTING ACTIVITIES	−500,000	−1	−29,774	−5,156	−48,892
Repayments of finance agreement	−971,231	−870,073	−1	—	—
Proceeds from exercise of warrants	—	341,865	2	130,000	82,056
Proceeds from private placements	2	3	4	—	5
Proceeds from issuance of promissory notes	0	4	0	—	—
Proceeds from notes payable	7	4	—	—	—
NET CASH PROVIDED BY FINANCING ACTIVITIES	8	11	5	4	33
Effect of exchange rates on cash	−135,892	60,141	−8,395	−5,240	26,111
NET INCREASE (DECREASE) IN CASH	−127,767	−2	−7	−11	12
Interest	24,555	20,128	352,334	79,716	89,224
Income Taxes	0	0	0	34	37
Contingent Shares issued pursuant to Acquisition Agreement	0	0	3	—	—
Cancellation of restricted stock awards	83	—	—	—	—
Finance agreement entered into in exchange for prepaid assets	1	906,834	1	666,875	607,250
Conversion of note payable for issuance of preferred stock	0	2	0	—	—
Note payable settled through non-cash exercise of warrants	0	2	0	—	—
Debt discount related to notes payable	24,954	339,342	0	—	—
Common shares issued upon acquisition	6	136	0	—	—
Contingent consideration issued upon acquisition	0	21	0	—	—
Common shares issued upon settlement of debt	0	10	0	—	—
Earn out shares issued in settlement of contingent liability	0	11	0	—	—
Options issued in settlement of debt	0	489,000	0	—	—
Settlement of notes payable	0	418,503	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro